SCHEMBL1642189

SCHEMBL1642189

O=C(O)CNC(=O)c1c(O)c(C(=O)NCC2CC2)c(O)n(CC2CCCCC2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.48
EGLN1 Q9GZT9 11/20 0.48
EGLN3 Q9H6Z9 7/20 0.48
EGLN2 Q96KS0 6/20 0.48
OGFOD1 Q8N543 1/20 0.48
HIF1AN Q9NWT6 1/20 0.48
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
BBOX1 O75936 1/20 0.41
ASPH Q12797 1/20 0.41
KDM8 Q8N371 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
BCL2 P10415 1/20 0.38
BCL2L1 Q07817 1/20 0.38
MCL1 Q07820 1/20 0.38
BCL2A1 Q16548 1/20 0.38
FEN1 P39748 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642373 0.89 CNR1 (0.48) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL1642306 0.88 EGLN1 (0.47) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL1640710 0.85 EGLN1 (0.45) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL1641194 0.83 EGLN1 (0.67) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL12727520 0.79 EGLN3 (0.52) HIF1AEGLN1EGLN3EGLN2BBOX1
SCHEMBL1642357 0.79 EGLN3 (0.50) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL1641951 0.79 KDM4E (0.49) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL1641473 0.78 HIF1A (0.49) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL3424007 0.76 EGLN1 (0.74) HIF1AEGLN1EGLN3EGLN2OGFOD1
SCHEMBL8244798 0.76 HIF1A (0.67) HIF1AEGLN1BBOX1ASPHKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 HIF1A 4/4885EGLN1 6/4885EGLN3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.